Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
ACG Case Rep J ; 9(12): e00942, 2022 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-36628369

RESUMO

Segmental arterial mediolysis (SAM) is a rare nonatherosclerotic and noninflammatory disease that often affects medium to large-sized arteries. We report a case of SAM involving bilateral hepatic arteries in an elderly woman. Although her initial presentation mimicked vasculitis, the clinical course and imaging led to the diagnosis of SAM. She was treated with coil embolization and stenting of the involved hepatic vessel leading to dramatic clinical improvement. It should be differentiated from vasculitis because there is no role of steroids in the management of SAM.

2.
BMJ Case Rep ; 14(9)2021 Sep 20.
Artigo em Inglês | MEDLINE | ID: mdl-34544705

RESUMO

Immune-mediated necrotising myopathy is a subtype of idiopathic inflammatory myopathy characterised by muscle fibre necrosis without significant inflammatory infiltrate. Anti-3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGCR) myopathy is seen in 6%-10% of idiopathic inflammatory myopathy and is diagnosed in the context of elevated serum creatine kinase levels, proximal muscle weakness and anti-HMGCR autoantibodies. We recently encountered a 61-year-old man with anti-HMGCR myopathy with an atypical skin manifestation, partially responsive to triple therapy with steroids, intravenous immunoglobulin (IVIG) and rituximab. To our knowledge, there have been only four reported cases of skin rash associated with anti-HMGCR myopathy. Our case demonstrates the importance of recognising atypical manifestations of anti-HMGCR myopathy. Early addition of IVIG and rituximab is also critical in patients not responding to steroid monotherapy. Delay in achieving remission leads to prolonged steroid use, lower likelihood of beginning physical therapy and overall worse clinical outcomes.


Assuntos
Doenças Musculares , Miosite , Coenzimas , Humanos , Hidroximetilglutaril-CoA Redutases , Masculino , Pessoa de Meia-Idade , Doenças Musculares/induzido quimicamente , Doenças Musculares/diagnóstico , Doenças Musculares/tratamento farmacológico , Miosite/induzido quimicamente , Miosite/diagnóstico , Miosite/tratamento farmacológico , Oxirredutases
3.
Neurotox Res ; 39(1): 36-41, 2021 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-32221851

RESUMO

Cisplatin is a platinum-based chemotherapy compound effective against a variety of cancers. However, it can cause increased reactive oxygen species (ROS) production in auditory and vestibular tissue leading to permanent hearing and balance loss. The amino acid, L-serine, has been shown to reduce ROS in some tissue types. In this project, we first investigated whether L-serine could reduce cisplatin-mediated ROS generation in zebrafish utricular tissue culture using spectrophotometry and the fluorescent ROS detector dye, H2DCFDA. Then, we examined whether L-serine could prevent the effect of cisplatin against cellular viability in the mouse auditory hybridoma cell line, HEI-OC1, using the spectrophotometric (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) (MTT) assay. As a final step, we used H2DCFDA dye and flow cytometry analysis to determine if L-serine could counteract the effect of cisplatin on ROS production in this cell line. We found that cisplatin and L-serine treatment may influence ROS production in utricular tissue. Further, although L-serine did not counteract the effect of cisplatin against HEI-OC1 cellular viability, the amino acid did prevent the platinum compound's effect to increase ROS in these cells. These results suggest that L-serine may act in auditory and vestibular tissues as an effective protectant against cisplatin-mediated toxicity.


Assuntos
Cisplatino/toxicidade , Hibridomas/efeitos dos fármacos , Hibridomas/metabolismo , Espécies Reativas de Oxigênio/metabolismo , Sáculo e Utrículo/efeitos dos fármacos , Sáculo e Utrículo/metabolismo , Serina/administração & dosagem , Animais , Linhagem Celular Tumoral , Feminino , Masculino , Técnicas de Cultura de Tecidos , Peixe-Zebra
4.
Neurotoxicology ; 79: 104-109, 2020 07.
Artigo em Inglês | MEDLINE | ID: mdl-32413439

RESUMO

Cisplatin is a platinum(II) chemotherapy drug that can cause the side-effect of ototoxicity and hearing loss. The monofunctional platinum(II) complexes, phenanthriplatin and pyriplatin, have recently been investigated as anti-cancer agents but their side-effects are largely unknown. Here, we used the auditory hybridoma cell line, HEI-OC1, to investigate the ototoxicity of cisplatin, phenanthriplatin and pyriplatin. The effect of these compounds against cellular viability, on reactive oxygen species (ROS) production, mitochondrial membrane polarization, caspase-3/7 activity, DNA integrity and caspase-12 expression were measured using spectrophotometric, flow cytometric and blot analyses. We found that the monofunctional complexes and cisplatin decreased cellular viability. All three compounds increased ROS yield at 24 h, but at 48 h, ROS levels returned to normal. Also, the compounds did not depolarize the mitochondrial membrane. All three compounds reduced caspase-3/7 activity at 24 h; cisplatin increased caspase-3/7 activity and caused apoptosis at 48 h. Caspase-12 expression was associated with all three compounds. In summary, the monofunctional complexes may cause ototoxicity like cisplatin. Phenanthriplatin and pyriplatin may cause ototoxicity initially by inducing ROS production, but they may also signal through distinct apoptotic pathways that do not integrate caspases-3/7, or may act at different time-points in the same pathways.


Assuntos
Antineoplásicos/toxicidade , Apoptose/efeitos dos fármacos , Caspases/metabolismo , Cóclea/efeitos dos fármacos , Compostos Organoplatínicos/toxicidade , Fenantridinas/toxicidade , Animais , Caspase 12/metabolismo , Caspase 3/metabolismo , Caspase 7/metabolismo , Linhagem Celular , Cóclea/metabolismo , Cóclea/patologia , Hibridomas , Camundongos , Ototoxicidade , Espécies Reativas de Oxigênio/metabolismo , Transdução de Sinais
5.
Mayo Clin Proc Innov Qual Outcomes ; 4(1): 31-39, 2020 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-32055769

RESUMO

OBJECTIVE: To determine independent risk factors for inappropriate antibiotic prescribing for acute respiratory tract infections (ARIs) in internal medicine (IM) residency-based primary care offices. PATIENTS AND METHODS: A retrospective study was conducted to measure antibiotic prescribing rates, and multivariable analysis was utilized to identify predictors of inappropriate prescribing among patients presenting to IM residency-based primary care office practices. Patients with an office visit at either of 2 IM residency-based primary care office practices from January 1, 2016, through December 31, 2016, with a primary encounter diagnosis of ARI were included. RESULTS: During the study period, 911 unique patient encounters were included with 518 for conditions for which antibiotics were considered always inappropriate. Antibiotics were not indicated in 85.8% (782 of 911) of encounters. However, antibiotics were prescribed in 28.4% (222 of 782) of these encounters. Inappropriate antibiotic prescribing occurred in 111 of 518 (21.4%) encounters for conditions for which antibiotics are always inappropriate. Using multivariable logistic regression analysis to assess for independent risk factors when adjusted for other potential risk factors for office visits at which antibiotics were not indicated, IM resident-associated visits (odds ratio, 0.25; 95% CI, 0.18-0.36) was the only variable independently associated with lower risk of inappropriate antibiotic prescribing. CONCLUSION: For ARI visits at which antibiotics were not indicated, IM resident comanagement was associated with lower rates of inappropriate prescribing.

SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...